Destiny Pharma, a Brighton, UK-based pharmaceutical company, received £2.8m in funding.
Backers included Angel CoFund and other UK investors.
The company intends to use the funds a clinical trial for its lead drug, XF-73, to prevent post-surgical Staphylococcal infections.
Founded in 1997 and led by Dr Bill Love, CEO, Destiny Pharma focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action, which seek to address antibiotic resistance. Through its business network and strategic partnerships the company intends to globally commercialize candidates from the XF Drug platform, which are differentiated by design from traditional antibiotics.